Penicillin-Susceptible Group B Streptococcal Clinical Isolates with Reduced Cephalosporin Susceptibility | Zendy

Noriyuki Nagano | Zendy; Yukiko Nagano | Zendy; Masami Toyama | Zendy; Kouji Kimura | Zendy; Keigo Shibayama | Zendy; Yoshichika Arakawa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Penicillin-Susceptible Group B Streptococcal Clinical Isolates with Reduced Cephalosporin Susceptibility

Author(s) -

Noriyuki Nagano,

Yukiko Nagano,

Masami Toyama,

Kouji Kimura,

Keigo Shibayama,

Yoshichika Arakawa

Publication year - 2014

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.01291-14

Subject(s) - ceftizoxime , penicillin , cephalosporin , microbiology and biotechnology , penicillin binding proteins , streptococcaceae , cefaclor , antibacterial agent , amino acid substitution , antibiotics , biology , biochemistry , gene , mutant

We characterized penicillin-susceptible group B streptococcal (PSGBS) clinical isolates exhibiting no growth inhibition zone around a ceftibuten disk (CTB(r) PSGBS). The CTB(r) PSGBS isolates, for which augmented MICs of cefaclor and ceftizoxime were found, shared a T394A substitution in penicillin-binding protein 2X (PBP 2X) and a T567I substitution in PBP 2B, together with an additional G429S substitution in PBP 2X or a T145A substitution in PBP 1A, although the T145A substitution in the transglycosidase domain of PBP 1A would have no effect on the level of resistance to ceftibuten.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research